ArticleArchives of dermatological research2025
The diagnostic potential of Asprosin and Meteorin-like proteins in basal and squamous cell carcinomas.
Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Serum asprosin levels as a potential prognostic biomarker in COVID-19: insights for future respiratory viral pandemics.BMC infectious diseases · 2025Article
- Effects of nerolidol on serum cytokines in acute myocardial infarction: insights into the asprosin, spexin, and DARS2 antibodies in the brain cortex.Molecular biology reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-melanoma skin cancer (NMSC) is the most prevalent malignancy worldwide, encompassing primarily BCC and SCC. Differentiating between these two carcinomas and distinguishing them from normal skin tissue can pose diagnostic challenges in certain cases. Adipokines, as regulators of various biological processes, have garnered attention for their potential roles in tumorigenesis. Asprosin (Asp) and Meteorin-like (Metrnl) are newly identified proteins implicated in several diseases, including cancer. Their potential contribution to the pathogenesis of skin cancers such as BCC and SCC remains underexplored. This study aimed to evaluate the expression profiles of Asp and Metrnl in BCC and SCC and to assess their potential utility as diagnostic biomarkers. The expression of Asp and Metrnl proteins was examined by immunohistochemical staining in biopsy samples from 60 control, 60 BCC, and 60 SCC cases obtained from the archive of the Pathology Laboratory of Malatya Turgut Ozal University Training and Research Hospital. Asp immunoreactivity was higher in BCC tissues compared to the other two groups, and it was statistically higher in SCC tissues compared to healthy control tissues. Metrnl immunoreactivity was also higher in BCC tissues compared to the other two groups, and statistically significant in SCC tissues when compared to healthy control tissues. The findings suggest that Asp and Metrnl proteins may serve as valuable biomarkers for distinguishing between BCC and SCC, the two most common non-melanoma skin cancers encountered in routine dermatopathology practice. These adipokines may also provide insights into the underlying pathophysiology of these malignancies, offering potential avenues for diagnostic and therapeutic advancements.
Indexed as
Identifiers
40095046What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.